Cytochrome P450 3A1 (CYP3A1)

Cytochrome P450 3A1 (CYP3A1) is a member of the cytochrome P450 superfamily of enzymes, specifically within family 3, subfamily A. It functions as a heme-thiolate monooxygenase critical for the oxidative metabolism of a variety of structurally diverse compounds, including drugs, steroids, fatty acids, and xenobiotics. CYP3A1, originally characterized in rats, is a close ortholog of human CYP3A4, which is responsible for the metabolism of a majority of clinically used drugs[7]. The enzyme is primarily localized in the endoplasmic reticulum membranes of liver cells, where it participates in NADPH-dependent electron transport pathways to catalyze substrate oxidation[1][7]. Due to its broad substrate specificity, CYP3A1 is frequently involved in metabolic drug-drug interactions, which can alter the pharmacokinetics and safety profiles of coadministered drugs through enzyme inhibition or induction[2][6][8]. CYP3A1 also plays roles in the metabolism of endogenous steroids and fatty acids, contributing to overall metabolic homeostasis[7]. Notes and clarifications: - Cytochrome P450 3A1 is primarily described in rodents, especially rats. In humans, the closest functional homolog is CYP3A4, which dominates drug metabolism[7]. - Drug interaction lists commonly refer to the human isoform (CYP3A4); CYP3A1 is functionally very similar, but drug lists may not map exactly. - For clinical, pharmacological, and translational contexts involving humans, CYP3A4 may be the more pertinent target. Here, the information pertains specifically to CYP3A1 as originally requested.

Other names

CYP3A1Cytochrome P-450 3A1Cytochrome P450 family 3 subfamily A member 1

Drugs may be substrates (metabolized by CYP3A1), inhibitors (reduce CYP3A1 activity, raising substrate drug levels), or inducers (increase CYP3A1 expression or activity, lowering substrate drug levels)[2][6][8].